1. Scrip
  2. >>Therapy Areas
  3. >>Genitourinary

Novartis’s Iptacopan Pulls Ahead In Race To Fill Nephrology Unmet Need

Phase II Trial In Rare Kidney Disease Is A Success

 
• By Ayisha Sharma

The first-in-class candidate met two primary endpoints in a Phase II trial for C3 glomerulopathy, suggesting potential edge over ChemoCentryx and Vifor’s competitor avacopan.  

Iptacopan Is Novartis' Lead Nephrology Asset • Source: Alamy

New Phase II data for Novartis AG’s iptacopan has reinforced its potential in the rare disease C3 glomerulopathy (C3G) less than a year after ChemoCentryx, Inc. and Vifor Pharma Group’s competitor Tavneos (avacopan) disappointed with its topline Phase II data. The Swiss firm is now forging ahead with the Phase III APPEAR-C3G study for the product in C3G.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Genitourinary

Still Looking For A Gene Therapy Hit, Syncona Backs Purespring In IgA Nephropathy Market

 
• By Andrew McConaghie

Purespring has just raised $105m from an investor syndicate who are betting it can develop the first gene therapy for kidney disease and learn from setbacks experienced in the space.

REGENCY Dandy for Roche In Lupus Nephritis

 
• By Elizabeth Cairns

Gazyva could add the autoimmune condition to its label following a Phase III hit, but it might struggle to differentiate itself from Benlysta and Lupkynis.    

AstraZeneca Believes Size Matters In Amyloidosis

 
• By Elizabeth Cairns

Following the pivotal data on Alnylam’s Amvuttra, all eyes turn to the next amyloidosis readout – that of AstraZeneca and Ionis’ Wainua. And the UK major’s ambitions do not stop there.    

Pfizer And Flagship’s Quotient To Seek Out New Heart And Kidney Drugs

 
• By Andrew McConaghie

The big pharma’s second selection in the alliance shows novel cardiovascular therapies are high on its priority list

More from Therapy Areas

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

 
• By Kevin Grogan

Adstiladrin sales hit €70m in first full year on the market

Multiple Tactics Likely Needed To Control Obesity Drug Costs

 
• By Alaric DeArment

ICER’s new white paper pointed to estimates that the GLP-1 drugs may result in more than $100bn in annual spending, highlighting the need to rein in costs.

Cartesian Maps Out CAR-T Strategy With Simpler Logistics In Mind

 
• By Alaric DeArment

The company announced positive Phase IIb data for Descartes-08 in myasthenia gravis, with especially strong efficacy among patients without prior biologic treatment.